JOSEPH J. MANNING - 25 Aug 2022 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Joseph J. Manning by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
25 Aug 2022
Net transactions value
-$1,803,533
Form type
4
Filing time
26 Aug 2022, 17:46:09 UTC
Previous filing
02 Mar 2022
Next filing
09 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $1,021,555 +23,008 +40% $44.40 80,143 25 Aug 2022 Direct F1
transaction ABT Common shares without par value Sale $2,415,704 -23,008 -29% $104.99 57,135 25 Aug 2022 Direct F2
transaction ABT Common shares without par value Sale $409,384 -3,890 -6.8% $105.24 53,245 25 Aug 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -23,008 -50% $0.000000 23,008 25 Aug 2022 Common Shares 23,008 $44.40 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Since the date of the reporting person's last ownership report, he transferred 3,738 shares and employee stock options to purchase 69,500 shares in the aggregate to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.59 to $105.37, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).